在妇科瘤中的新型雄激素受体结合变体7
概括
在两种罕见的妇科癌症中发现了雄激素受体变体7 (AR-V7). 这一发现表明AR-V7可能是针对这些癌症的向治疗的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 妇科 妇科医生 妇科
背景情况:
- 雄激素受体拼接变体7 (AR-V7) 是一个截断的AR mRNA变体.
- AR-V7是针对雄激素受体向治疗的潜在预测生物标志物.
- 在各种癌症中发现了AR-V7,包括前列腺癌和乳腺癌.
研究的目的:
- 研究在妇科癌症中AR-V7的存在和特征.
- 确定AR-V7作为妇科恶性瘤生物标志物的潜在作用.
主要方法:
- 针对性的RNA测序被用于检测AR-V7.7.
- 组织病理学检查描述了瘤的特征.
- 进行了DNA甲基化分析.
主要成果:
- 在两个妇科癌症中检测到AR-V7:一个在子宫下部段,一个在卵巢.
- 子宫瘤是一种不分化的癌症,而卵巢瘤显示出形和固体结构.
- 表观遗传分析显示,这些AR-V7阳性妇科癌和AR-V7阳性乳腺癌之间存在相似之处.
结论:
- 在罕见的妇科癌中可能存在AR-V7.
- 在这些特定的妇科癌症中,AR-V7可以作为针对性治疗的预测生物标志物.
- 这些发现表明AR-V7阳性妇科和乳腺癌之间存在潜在联系.
更多相关视频
10:06Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
9.0K
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
10.7K
相关概念视频
RNA Splicing
56.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.3K
Alternative RNA Splicing
21.1K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.1K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Loss of Tumor Suppressor Gene Functions
4.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Receptor Tyrosine Kinases
12.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.7K
